AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
_02_05_2025_05_53_40_418159.jpg)
Highlights
BVF Partners exits Syntara citing fund size constraints, not program performance
Trial data for myelofibrosis drug candidate shows continued progress
Syntara to discuss future clinical development path with US FDA
Syntara Ltd (ASX:SNT), listed on the ASX 300, has announced the exit of long-term US-based biotech investor BVF Partners, marking a notable development in the company’s shareholder profile while reaffirming progress in its late-stage oncology research.
The San Francisco-based fund exited its stake in Syntara via a block trade. While the exit influenced market movements, the company has emphasised that the decision reflects a shift in BVF’s capital allocation strategy rather than any change in confidence toward Syntara’s clinical direction.
Institutional Reshuffle Follows Broader Exit from Australian Market
BVF Partners, which manages a multibillion-dollar portfolio, has reportedly exited its entire exposure to ASX-listed entities. The divestment from Syntara follows similar exits from other biotechnology firms, including Actinogen Medical and Opthea.
Syntara noted that existing institutional holders absorbed the shares released through the block transaction. CEO Gary Phillips stated the decision was aligned with the fund’s scaling requirements rather than reflective of company-specific sentiment, with BVF consistently supportive of Syntara’s scientific progress.
Trial for Myelofibrosis Therapy Reports Positive Outcomes
Syntara continues to report progress from its phase II trial focused on myelofibrosis, a rare and severe bone marrow cancer. The trial is evaluating SNT-5505 in combination with ruxolitinib, the current standard of care.
The data released shows symptomatic and structural improvements in patients with high disease burdens. The trial enrolled individuals who had previously been treated with ruxolitinib, with measurable improvements observed in spleen size and symptom severity over the course of the treatment timeline.
Dropout levels in the study were consistent with similar trials in the field, and the company maintains that the treatment duration and patient response align with known disease progression benchmarks.
Next Steps Include Engagement with US Regulatory Authorities
Following the phase II outcomes, Syntara plans to engage with the US Food and Drug Administration during the upcoming quarter. The discussions will centre around designing the next stage of clinical development, which may include a pivotal phase 2c/3 study.
This step will be essential in defining the regulatory pathway for SNT-5505, especially given the unmet clinical need in treating advanced myelofibrosis cases. The company’s trial developments and strategic communications with regulatory bodies will likely remain key focal points in the coming months.
